Chemveda Life Sciences

What Chemveda Life Sciences does

Chemveda Life Sciences is a privately held, founder-owned CRO-CDMO founded in 2008 and headquartered in Hyderabad, India, delivering integrated chemistry services to the global pharmaceutical and biotechnology industries. The company operates from three scale-specific units in Hyderabad (R&D Unit 1 in Uppal, R&D Unit 2 in Mallapur, and a GMP-certified manufacturing facility in Choutuppal) plus US offices and labs in San Diego and a Boston sales office in Bridgewater, Massachusetts, and — as of April 2026 — a European discovery site at the University of Dundee's Life Sciences Innovation Hub in Scotland.

Its service platform spans Discovery Chemistry Services (synthetic chemistry, medicinal chemistry, PROTACs and targeted protein degraders, ADC linker-payload synthesis, oligonucleotide synthesis, peptide synthesis including macrocyclic and stapled peptides, nucleoside and nucleotide chemistry, asymmetric synthesis, photoredox chemistry, and electrochemistry) and Development & Manufacturing Services (process R&D, custom synthesis, route scouting, analytical and impurity characterization, stability studies, and GMP manufacturing from kilo to multi-ton scale). The company also offers integrated scale-up across reactor volumes from 500 mL to 200 L. Quality credentials include ISO 9001:2015 certification and GMP certification from India's CDSCO/DGCI.

Chemveda generates revenue on a professional services basis through Full-Time Equivalent (FTE) and Fee-for-Service (FFS) engagement models, anchored by long-term pharma/biotech relationships. The company cites a 40%+ client retention rate over five years and more than 100 cumulative biotech customers across pharmaceutical, biotechnology, agrochemical, cosmeceutical, and academic end-markets. Scientific leadership includes founder and CEO Dr. Bheema Rao Paraselli (24+ years of industry experience, 75+ patents, with multiple clinical candidates advanced at Dr. Reddy's and Syrrx/Takeda) and an advisory board comprising Prof. K.C. Nicolaou, Prof. Phil S. Baran, and Prof. Jin-Quan Yu. The company employs roughly 450 scientists with a PhD:MS ratio of 1:5 and a total global headcount cited at 600 employees.

Name

Chemveda Life Sciences

Legal name

Chemveda Life Sciences India Pvt. Ltd.

Website

https://chemvedals.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

251–500 employees

Short description

Chemveda Life Sciences is a Hyderabad, India-based founder-owned CRO-CDMO providing integrated synthetic, medicinal, and process chemistry services — including PROTACs, ADC linkers, oligonucleotides, peptides, and GMP manufacturing — to global pharmaceutical, biotechnology, and life-sciences clients.

Ownership category

akta.pro rank

Product category

Contract Research and Manufacturing Services (CRO/CDMO)

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

akta.pro secondary industries

Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE), Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA) (HLAGAKAJ)

Keywords

• Contract research services
• Drug discovery chemistry
• Process development manufacturing
• Custom synthesis services
• Pharmaceutical CDMO services

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Research Services: Service-based revenue model providing chemistry contract research services to pharmaceutical, biotechnology, agrochemical, cosmeceutical, academic, and life science organizations. Services include discovery chemistry, process R&D, custom synthesis, and analytical support. Company utilizes flexible FTE and FFS (Fee-for-Service) engagement models.
2. Contract Development and Manufacturing: CDMO services covering process development through commercial manufacturing of APIs, intermediates, and key starting materials. Revenue generated through project-based fees, FFS, and FTE models for both non-GMP and GMP manufacturing.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Chemveda Life Sciences is a CRO-CDMO providing integrated chemistry services spanning drug discovery, process research and development, and manufacturing. Its core offerings include Discovery Chemistry Services (synthetic chemistry, PROTACs, scale-up chemistry, nucleosides/nucleotides, peptides, ADC linker-payloads, and oligonucleotides), Process Research & Development Services, and Manufacturing Services from non-GMP to GMP scale. The company delivers these services to pharmaceutical, biotechnology, agrochemical, cosmeceutical, academic, and life sciences organizations globally through flexible FTE (Full-Time Equivalent) and FFS (Fee-for-Service) engagement models.

Product overview

Chemveda Life Sciences is a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) offering an integrated platform of chemistry services. The core offering comprises Discovery Chemistry Services (including Synthetic Chemistry, PROTACs, Scale Up Chemistry, Nucleosides & Nucleotides, Peptides, ADC-Linkers, and Oligonucleotides) and Development Services (Process R&D and Manufacturing). The company provides comprehensive chemistry solutions spanning from early-stage discovery through process development to commercial manufacturing, supporting pharmaceutical, biotechnology, agrochemical, and academic clients globally.

Differentiator

Problem solved

Functional benefit

Products and services

• Discovery Chemistry Services
• Synthetic Chemistry
• PROTACs (Targeted Protein Degraders)
• Scale Up Chemistry Services
• Nucleosides and Nucleotides
• Peptides
• ADC Linkers and Payloads
• Oligonucleotides
• Process Research and Development Services
• Manufacturing Services
• Analytical Services
• Stability Studies
• Impurity Characterization Services

Quantifiable outcome

• 40%+ client retention rate over five years
• +2 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature11 records

Partnerships

Two partnerships are on record, tiered major and supporting.

• University of DundeemajorStrategic or Co-development Partner · 5 March 2026Chemveda establishing European operations at University of Dundee's Life Sciences Innovation Hub. Dundee has been ranked UK's top university for Biological Sciences in recent Research Excellence Framework exercises. The hub provides state-of-the-art laboratory accommodation for Chemveda's integrated discovery platform.
• Dundee City CouncilsupportingStrategic or Co-development Partner · 5 March 2026Dundee City Council collaborated with the University of Dundee and Scottish Enterprise to attract Chemveda as the first FDI success for the Life Sciences Innovation Hub.

Scale indicators11 records

Recent moves4 records

Expansion highlights5 records

Regional players

• Sygnature Discovery: UK-based CRO providing integrated drug discovery services with strong medicinal chemistry, DMPK, and computational chemistry capabilities. Comparable to Chemveda's discovery chemistry focus, but anchored in the UK market that Chemveda is now entering via Dundee.

Direct peers

• Piramal Pharma Solutions: India-headquartered CDMO offering API development and manufacturing, including complex chemistry and HPAPI capabilities. Directly comparable to Chemveda's process R&D and GMP manufacturing services; Chemveda's AVP PR&D previously held Director QbD role at Piramal.
• Sai Life Sciences: India-based integrated CRO-CDMO spanning discovery, process R&D, and GMP manufacturing of APIs and intermediates. Directly comparable to Chemveda on scope, scale, and target customer base; multiple Chemveda leaders previously held leadership roles at Sai Life.
• Aurigene Pharmaceutical Services: India-based CRO/CDMO providing discovery chemistry, custom synthesis, process R&D, and GMP manufacturing for global pharma/biotech customers. Comparable to Chemveda on integrated service scope and target customer profile.
• Aragen Life Sciences: Indian-headquartered CRO/CDMO offering discovery chemistry, process R&D, and manufacturing services across small molecules and biologics. Highly comparable in modality coverage, customer profile (global pharma/biotech), and India-anchored delivery model; several Chemveda VPs previously worked at Aragen/GVK.
• Jubilant Biosolutions (Jubilant Chemsys/Innovation): Indian CRO offering discovery chemistry, medicinal chemistry, and integrated drug discovery services to global pharma/biotech. Directly comparable on modality coverage and customer base; Chemveda leadership includes alumni from Jubilant.
• BioDuro-Sundia: Asia-based integrated CRO/CDMO providing discovery chemistry, process R&D, and manufacturing services to global pharma/biotech. Highly comparable offering and customer set; Chemveda's EVP Frank Ruebsam previously served as SVP at BioDuro-Sundia for 13 years.

Broad incumbents

• Pharmaron: Global CRO/CDMO with end-to-end drug discovery, development, and manufacturing services across small molecules and biologics. Overlaps materially with Chemveda's discovery and CDMO offerings, but operates at significantly larger scale across US, UK, and China.
• WuXi AppTec / WuXi STA: Global CRO/CDMO operating the largest discovery chemistry bench and one of the largest API manufacturing footprints globally. Material overlap with Chemveda's service lines, but at vastly larger scale and broader end-to-end coverage.
• Curia (formerly Albany Molecular Research / AMRI): Global CRO/CDMO with discovery chemistry, custom synthesis, and API manufacturing services for pharma/biotech customers. Comparable service overlap with Chemveda across the discovery-to-commercial arc, but at meaningfully larger commercial scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/chemveda
• YouTubeyoutube.com/@chemvedalifesciences9627
• Facebookfacebook.com/chemveda.lifesciences
• LinkedInlinkedin.com/company/chemveda
• Instagraminstagram.com/chemvedals

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chemveda Life Sciences